From the Bench- The Lab of Dr. Mark Albers at Mass General Hospital

An article from MGH’s Sean M. Healey & AMG Center for ALS, highlights two clinical trials from Mark Alber’s lab at MGH: the Neurodegenerative Alzheimer’s Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial and the Therapeutic Repurposing in ALS (TRIALS) clinical trial program. 

The NADALS trial is fully enrolled, with results expected in Q4 2025. The TRIALS program is using existing drugs to identify effective therapies for ALS. By repurposing FDA approved drugs, TRIALS could identify promising drug candidates that have already been proven safe, potentially enabling a more rapid route for new ALS therapies. 

Read more at Mass General